Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment

•The differences of BSA affected the optimal dose of osimertinib.•BSA does not affect severe side effects, but mild side effects involving the body.•The PFS of osimertinib had no significant difference by BSA.•Dose reduction to control AEs should be considered especially in BSA

Saved in:
Bibliographic Details
Published in:Cancer treatment and research communications 2024-01, Vol.40, p.100836, Article 100836
Main Authors: Tanaka, Saki, Tamiya, Motohiro, Nishiuma, Satoshi, Nakamura, Sayaka, Nozaki, Keisuke, Watanabe, Naoko, Itoh, Chisae, Kadokawa, Yukio, Takeda, Kenji, Takahashi, Kozo, Miyazaki, Akito, Kawamura, Takahisa, Kunimasa, Kei, Inoue, Takako, Nishino, Kazumi, Takagi, Mari
Format: Article
Language:English
Subjects:
Adverse events
Body surface area
Lung cancer treatment
Progression-free survival
Safety
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The differences of BSA affected the optimal dose of osimertinib.•BSA does not affect severe side effects, but mild side effects involving the body.•The PFS of osimertinib had no significant difference by BSA.•Dose reduction to control AEs should be considered especially in BSA
ISSN:2468-2942
2468-2942
DOI:10.1016/j.ctarc.2024.100836